TriangleNCT01553149 · OUTCOME
Event-free Survival [EFS]
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- Percent Probability
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 3 years after study enrollment
What was measured
Estimated 3-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact.
Analysis population: Only eligible patients are considered in the analysis of this outcome measure
Groups in this outcome
Arm I (Low-dose Lenalidomide)
Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Lenalidomide: Given PO Pharmacological Study: Correlative studies
Arm II (High-dose Lenalidomide)
Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Lenalidomide: Given PO Pharmacological Study: Correlative studies
| Group | Source count |
|---|---|
| Arm I (Low-dose Lenalidomide) | 37 |
| Arm II (High-dose Lenalidomide) | 37 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Arm I (Low-dose Lenalidomide) | 37.84 | Not reported | 22.62 | 52.97 | Not reported |
| Arm II (High-dose Lenalidomide) | 39.41 | Not reported | 23.72 | 54.74 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 22.62
- upper Limit
- 52.97
- value
- 37.84
- group Id
- OG001
- lower Limit
- 23.72
- upper Limit
- 54.74
- value
- 39.41
- denoms
- counts
- group Id
- OG000
- value
- 37
- group Id
- OG001
- value
- 37
- units
- Participants
- description
- Estimated 3-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Lenalidomide: Given PO Pharmacological Study: Correlative studies
- id
- OG000
- title
- Arm I (Low-dose Lenalidomide)
- description
- Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity. Lenalidomide: Given PO Pharmacological Study: Correlative studies
- id
- OG001
- title
- Arm II (High-dose Lenalidomide)
- param Type
- NUMBER
- population Description
- Only eligible patients are considered in the analysis of this outcome measure
- reporting Status
- POSTED
- time Frame
- Up to 3 years after study enrollment
- title
- Event-free Survival [EFS]
- type
- SECONDARY
- unit Of Measure
- Percent Probability
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice